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shown previously, tumour cell production of vascular endothelial growth factor might be a
major cause of the formation of malignant ascites. Intraperitoneal bevacizumab could there-
fore be an option for symptom control in refractory ascites.
Patients and methods: Patients with advanced gastrointestinal cancer and malignant ascites
who had undergone paracentesis at least twice within the past 4 weeks were randomly assigned
in a 2:1 ratio to intraperitoneal bevacizumab (400 mg absolute) or placebo after paracentesis.
During the 8-week treatment period, a minimum interval of 14 d was kept between the appli-
cations of the study drug. Primary end-point was paracentesis-free survival (ParFS).
Results: Fifty-three patients (median age 63 years) were randomised. Forty-nine patients
received at least one study drug application and qualified for the main analysis. Thef Hematology and Oncology, University of Halle-Wittenberg, Ernst-Grube-Str. 40, 06120 Halle, Germany.
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similar with 20/33 (61%) on bevacizumab and 11/16 (69%) on placebo. Median ParFS was
14 d (95% confidence interval [CI]: 11e17) in the bevacizumab arm and 10.5 d (95% CI: 7
e21) on placebo (hazard ratio 0.74, 95% CI: 0.40e1.37; P Z 0.16). The longest
paracentesis-free period was 19 d on bevacizumab (range 6e66 d) and 17.5 d in the placebo
arm (range 4e42) (P Z 0.85). Median overall survival was 64 d (95% CI: 45e103) on beva-
cizumab compared to 31.5 d (95% CI: 20e117) on placebo (P Z 0.31).
Conclusion: Intraperitoneal bevacizumab was well tolerated. Overall, treatment did not result
in a significantly better symptom control of malignant ascites. However, patients defined by
specific immune characteristics may benefit.
ª 2016 Elsevier Ltd. All rights reserved.1. Introduction
Despite major prognostic improvements in the palliative
treatment of patients with gastrointestinal cancer,
symptomatic malignant ascites, which occurs in up to
15% of these patients, remains a challenge in optimal
symptom management [1]. Fluid accumulation causes
severe impairing symptoms [2]. Its elimination is a
foremost goal and generally improves the patient’s
quality of life, or even may prolong survival [3]. Diuretic
therapy is effective in the beginning. Alternative options
such as intraperitoneal chemotherapy or targeted ther-
apies need further investigation.
With progressive disease, the fluid recurrence usually
accelerates, requiring more frequent paracenteses.
Stringently designed, randomised trials in this area are
rare. Except for catumaxomab, a trispecific monoclonal
antibody prolonging puncture-free periods [4], there is a
general lack of evidence on efficacy [2,5,6]. However,
catumaxomab is at present not generally available
anymore.
Besides mechanical obstruction and hormonal effects,
cytokine release seems to play a major role in the
pathophysiology of malignant ascites [1,6]. Recently
translational research as well as clinical results from
small case series have suggested a potential role of the
vascular endothelial growth factor (VEGF) in the
development process of malignant ascites [1,7].
The rationale of this placebo-controlled randomised
phase II study was to assess, whether the intraperitoneal
administration of the monoclonal anti-VEGF antibody
bevacizumab is able to impact on development of ma-
lignant ascites in order to improve symptom control in
patients with advanced gastrointestinal cancer.2. Patients and methods
2.1. Study design
This multicentre, placebo-controlled, double-blind rand-
omised phase II study was carried out according to theDeclaration of Helsinki and Good Clinical Practice
Guidelines and was approved by the appointed Ethical
Committee of each participating site. Written informed
consent was obtained from all patients before study
participation. Registration: ClinicalTrials.gov NCT012
00121.
2.2. Patient population
Patients aged 18 years with histologically confirmed
gastrointestinal cancer, with ascites were eligible. Ma-
lignant ascites had to be diagnosed either cytologically,
or as an exudate with total protein >30 g/L clinically
suggestive for malignant origin, or morphologically as
peritoneal carcinosis by imaging. Ascites had to be
clinically assessed to be non-responsive to both con-
ventional systemic treatment of the underlying disease,
and to diuretics, demanding at least two previous par-
acenteses within 4 weeks prior to enrolment were
required. Further inclusion criteria were Eastern
Cooperative Oncology Group performance score 3, a
life expectancy of at least 12 weeks, and no severe ab-
normalities with respect to haematology, clinical chem-
istry and urinalysis parameters. Major exclusion criteria
were bacterial peritonitis, haemorrhagic ascites, initia-
tion of new treatment with other antineoplastic agents
as already applied before inclusion (continuation of
ongoing treatment which did not result in sufficient as-
cites control was permitted), parallel treatment with
bevacizumab intravenous (i.v.), and standard contrain-
dications preventing bevacizumab treatment.
2.3. Treatment plan and assessments
Bevacizumab and placebo medication were manufac-
tured centrally, securing blind allocation to the study
patients following a concealed, computer-generated
randomisation list, in a 2:1 ratio.
Before inclusion of a patient into the study, a 4-week
screening period allowed for a stringent evaluation of
the patient regarding fulfilment of inclusion and exclu-
sion criteria (Fig. 1). In eligible patients the treatment
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centesis with study medication. The indication for the
following paracenteses was assessed by the treating
physician as needed for symptom control. With those,
up to four intraperitoneal administrations of bev-
acizumab (400 mg absolute dose in 100 ml NaCl 0.9%)
or placebo with a minimum interval of 14 d following
subsequent paracenteses, during a maximum period of 8
weeks were administered, after placement of an intra-
peritoneal catheter and removal of the maximum vol-
ume of ascites for symptom relief. In case of
unacceptable toxicity, treatment was prematurely dis-
continued. The following assessments were performed
before or after each study paracentesis and 4 weeks
thereafter: volume of ascites drained, performance sta-
tus, physical examination, body weight, quality of life
using the Functional Assessment of Chronic Illness
Therapy-Ascites Index (FACIT-AI) questionnaire [8],
supportive procedures, urinalysis, haematology, clinical
chemistry, activated partial thromboplastintime (aPTT),
international normalized ratio (INR), and adverse
events. Further puncture-free and overall survival (OS)
follow-up took place every 2 months for 1 year.
2.4. End-points and statistical aspects
The first primary end-point was paracentesis-free sur-
vival (ParFS), i.e. the time from randomisation to either
the second on-study paracentesis or to death, whichever
occurred first. Based on results by Heiss et al. [4] the
median ParFS in the untreated control group was ex-
pected to be approximately 14 d. In order to detect a
doubling of this interval to a median of 28 d by bev-
acizumab (hazard ratio [HR]: 0.5), a total number of 60
evaluable patients (40 in the experimental group, 20 in
the control group, according to the 2:1 randomisation)
with their event observed was required with a one-sided
type I error of 5% and a power of 80%. In order to allowWeek 1 to
1 to 4 adm
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Fig. 1. Study flowchart. *Minimum interval of 14 d between paracentesfor non-evaluable cases or drop-outs, a total of 72 pa-
tients were planned to be randomised. A second primary
end-point (‘best response’) was defined as the longest
paracentesis-free period within the 12-week main
observation period.
Secondary study end-points included: number of
paracenteses during the 12-week observation period;
quality of life; changes in performance status; OS,
defined as the time from randomisation until death;
rates of adverse events graded according to NCI com-
mon toxicity criteria (CTC) V. 3.0. Time-to-event data
were analysed by the KaplaneMeier method and
compared using the log-rank test [9]. Other continuous
data were compared using the Wilcoxon-Mann-Whitney
test. Within-group comparisons between different time
points or periods, were performed with the Wilcoxon
signed rank test. All tests except for the primary end-
points were considered explorative and are two-sided.
2.5. Luminex analysis
Ascites samples were collected from patients at the time
of baseline paracentesis and after a median of 2 weeks
(range 1e3 weeks) after administration of the first dose
of the study drug with the second routine paracentesis.
Samples were centrifuged at 1000 g for 10 min and
frozen at a minimum of 20 C until further use.
Luminex analyses were performed according to the
manufacturer’s instructions by EMD Millipore.
3. Results
3.1. Patient population and screening paracenteses
Between June 2010 and July 2013, a total of 157 patients
had been screened and 53 patients from 14 institutions
in Germany were randomised (Fig. 2). Due to the un-
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Fig. 2. Overview of patient disposition.
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closed for recruitment prematurely. The most frequent
reason for non-inclusion was a deterioration of the
general condition during screening, followed by failure
to gain informed consent, and a too low frequency of
paracentesis. Baseline demographic and clinical char-
acteristics are described in Table 1. The majority of theTable 1
Baseline characteristics and screening paracenteses.
Category
Age, median (range) [years]
Gender, female [n (%)]
Cancer type [n (%)]
 Cholangiocellular
 Colorectal
 Gastric
 Hepatocellular
 Pancreatic
 Unknown primary (Adeno-Ca)
Time since initial diagnosis of cancer, median [months]
Time since initial diagnosis of disseminated disease, median [months]
Number of previous antineoplastic regimens, median
Performance status [n (%)] (missing in three patients)
ECOG 0e1
ECOG 2
ECOG 3
Paracenteses during screening period (4 weeks):
Number, median (range)
Average interval between paracenteses, median (range) [d]
Maximum interval between paracenteses, median (range) [d]
Average ascites volume of last two paracenteses, median
ECOG, Eastern Cooperative Oncology Group.
a Following a late protocol amendment, patients were allowed to be r
screening. However, in the end only two patients had been randomised wipatients had pancreatic cancer. Inevitably, due to the
small patient numbers, some imbalances are present
between the groups, but paracentesis history parameters
were rather equally distributed.
3.2. Treatment exposure
Of the 208 recorded paracenteses during the observation
period 55% were followed by the administration of
study medication. Twenty percent of the patients
received the maximum number of four applications,
with rather equal increments of the study population
receiving one (bevacizumab/placebo: 30/38%, respec-
tively), two (21/25%), three (30/12%) or four applica-
tions (18/25%). Premature termination was mainly
caused by death (overall: 43%; bevacizumab: 39%, pla-
cebo: 50%). Other reasons included withdrawal of con-
sent (n Z 1), patient’s request (n Z 2), investigator’s
decision (n Z 3), or switching to a non-protocol ascites
treatment (n Z 1).
3.3. Efficacy
The median numbers of interventional paracenteses
during the study period were 4 (range: 1e17) and 3
(range: 1e8) for bevacizumab or placebo, respectively.
ParFS curves as the primary efficacy criterion are
shown in Fig. 3A, based on observed events in all of the
49 evaluable patients. There was no major difference
between the bevacizumab and the control group withStudy arm
Bevacizumab (n Z 33) Placebo (n Z 16)
62 (35e81) 65.5 (46e75)
15 (45) 4 (25)
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Fig. 3. Paracenteses-free (A) and overall survival (B).
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11e17 d) and 10.5 d (7e21 d). The HR amounts to 0.74
(95% CI: 0.40e1.37, P Z 0.16). Thus, the CI does not
exclude the prospectively anticipated target effect size
of HR Z 0.5. The ParFS result was clearly dominated
by paracentesis events, as in only eight patients (16%)
death occurred first before a second on-study para-
centesis. Likewise, the second primary efficacy end-
point, ‘best response’, did not show any major benefit in
the bevacizumab group, with a mean maximum period
without paracentesis of 22.9 d in the bevacizumab arm
(median: 19, range: 6e66 d) versus 18.7 d in the placebo
arm (median: 17.5, range 4e42 d; P Z 0.85).
In respect to OS the KaplaneMeier estimates suggest
a moderate trend in favour of bevacizumab (HR: 0.73,95% CI: 0.40e1.37), without reaching statistical signifi-
cance (P Z 0.31, Fig. 3B).
3.4. Effect of intraperitoneal bevacizumab treatment on
ascites cytokine/chemokine levels
Using Luminex technology, 13 soluble factors were
analysed in ascites samples from 22 patients of whom
pre- and post-treatment samples were available
(Fig. 4A). Overall, no significant changes in cytokine/
chemokine levels were detected. However, in the group
treated with bevacizumab we observed 8/16 patients
with at least 75% reduced ascites VEGF levels compared
to 0/6 patients in the placebo group. Within the patient
group treated with bevacizumab we further observed a
Reduced VEGF, n = 8, events = 8, median = 14 days
Stable VEGF, n = 8, events = 8, median = 11 days
A
B
Fig. 4. Cytokine levels in patients treated with bevacizumab or placebo. (A) Logarithmic fold changes of cytokines in ascites samples 2
weeks after initial paracentesis compared to the patients’ respective samples before treatment. (B) Paracentesis-free survival of patients
with ascites VEGF levels reduced by more than 75% compared to patients with ascites VEGF levels reduced by less than 75%. VEGF,
vascular endothelial growth factor; IL, interleukin; PDGF, platelet derived growth factor; TGF, transforming growth factor; RANTES,
regulated on activation, normal T-expressed, and presumably secreted; MIP, Macrophage Inflammatory Protein 1 alpha; IFNA, Inter-
feron alpha; IFNG, Interferon gamma.
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tients experiencing at least a 75% reduction in ascites
VEGF levels after treatment, compared to patients with
more stable VEGF levels.3.5. Safety
Due to the end-stage cancer status of all patients, a
plethora of adverse events were recorded with ques-
tionable relation to the study medication. The overall
frequency of events of CTC severity grades IIIeV was
not higher under bevacizumab (61%) than in the placebo
arm (69%). No case of hypertension was reported in
either treatment arm. One serious thromboembolic
event was reported in both arms (bevacizumab: 3%;
placebo: 6%). Gastrointestinal symptoms occurred moreoften in the bevacizumab group, with nausea reported in
45% versus 31%, and vomiting in 36% versus 0%.
Almost all of the recorded deaths were caused by pro-
gressive tumour disease (96%).3.6. Patient reported outcomes and supportive procedures
According to the specifications of the FACIT-AI, a
summary score was calculated from the 13 items,
ranging from 0 (worst) to 52 (best). Assessment of
quality of life was inevitably compromised by the major
loss process in this highly palliative situation. While 78%
of the forms were available at randomisation, the
questionnaires for week 8 were available in only 24% of
the patients. At baseline, i.e. before the first on-study
paracentesis, the total population showed a relevant
K. Jordan et al. / European Journal of Cancer 63 (2016) 127e134 133deterioration of health status due to ascites, with a
median score of 31 with a rather low variability (inter-
quartile range: 27e36). All pairwise comparisons of the
FACIT-AI between study weeks 0, 2 and 4 did not
indicate any significant difference (all P values >0.3), in
both arms as well as in the total population.
4. Discussion
This study is the first to test, in a randomised blinded
design, the potential benefit of intraperitoneal adminis-
tration of bevacizumab, in order to evaluate this
approach as a treatment option for symptom control in
the difficult treatment situation of advanced recurrent
ascites.
Bevacizumab was chosen as it is known that VEGF
plays a decisive role e not only in angiogenesis but also
in the pathophysiology of malignant ascites, by aug-
menting the permeability of microvasculature and of the
peritoneal membrane [7,10,11]. In animal models, the
expression level in cancer cells was markedly associated
with the production of ascites, while VEGF injections
increased the permeability of pre-existing small vessels
lining the peritoneum. Following promising data on
peritoneal influx blocking and impressive ascites re-
missions in in vivo models [7], a number of clinical case
series provided beneficial results for bevacizumab,
especially when given intraperitoneal (i.p.), in patients
with ascites secondary to a variety of solid tumours,
predominantly ovarian cancer. However, the sample
sizes were rather small, ranging from 1e9 patients [7,12].
For the largest series, published in abstract form, El-
Shami et al. reported resolution or at least distinctly
delayed reaccumulation of ascites in all of the nine pa-
tients enrolled, after only one i.p. application of 5 mg/kg
bevacizumab [13].
Those results stimulated the prospective and
controlled evaluation of i.p. administration in our trial.
One hypothesis was that i.p. application should build up
the highest concentration of the study drug within the
body compartment where malignant ascites is promoted
by VEGF secretion. Secondly, it is assumed that i.p.
agents are readily absorbed by the peritoneal tumour
tissue. Thirdly, this route was likewise successfully used
in most pre-clinical animal models [7,14]
The overall median ParFS, based on observed
events in all patients, was 13 d for the whole study
population (95% CI: 10e15 d). This is in accordance
with the assumed median of 14 d, which formed the
basis for the statistical design calculation of the trial.
Nevertheless, our observations could not confirm the
benefits suggested by the pilot studies, both with
respect to the time to the next recurrence event nor to
the duration of the subsequent paracentesis. Likewise,
no major differences between bevacizumab and pla-
cebo could be detected in the secondary clinical or
patient-reported outcomes. However, it might be ofinterest that we did observe a trend towards an
improved event-free survival in those patients
evidencing a substantial decrease in VEGF levels in
their malignant ascites following bevacizumab treat-
ment. A recently published abstract on a retrospective
series of 34 patients, without control group, with as-
cites secondary to gynaecological or gastrointestinal
cancers, suggested some prolongation of ParFS in
exsudative but not transudative types of ascites [15].
The poor median survival of about 1e2 months in
our overall population is quite in agreement with the
results from other similar patient series, i.e. with the
gastric cancer control group, experiencing recurrent
punctures, in the randomised catumaxomab trial [4],
and with the 3 months counted from first detection of
ascites in gastrointestinal cancer patients by Ayantunde
et al. [5].
In our study, the far advanced stage of ascites, in
combination with the short remaining lifetime, possibly
associated to the predominance of pancreatic cancer in
our cohort (55%, compared to only 7% in the catu-
maxomab study), may have prevented the detection of a
meaningful efficacy of the tested agent. Alternatively,
the chosen i.p. treatment could be suboptimal in this
setting [16]. Meanwhile, more promising results became
available from controlled studies on the effect of VEGF-
targeting therapies in ovarian cancer. In a randomised
study with 55 patients with ascites, i.v. aflibercept, an
inhibitor of both VEGF and placental growth factor
proved to be superior compared to placebo for the time
to repeat paracentesis but with an increased risk of in-
testinal perforations [17]. The large randomised AUR-
ELIA and GOG 0218 studies on i.v. bevacizumab
(which enrolled also patients without ascites) show
beneficial progression-free and OS effects in the sub-
groups with ascites [18,19]. However, in ovarian cancer,
the amount of ascites is comparatively small, especially
in the first-line setting, in which the ascites is often
detected (and removed) during surgery. In addition,
bevacizumab was given in combination with newly-
introduced chemotherapy.
A general drawback is the lack of standard defini-
tions of end-points in this disease setting, and their
subjectivity and variability between investigators. Un-
fortunately, the number of samples available for
extended translational analysis was limited. Neverthe-
less, there is some hint of a correlation of reduced ascites
VEGF level development in the bevacizumab group,
and slightly prolonged ParFS.
In conclusion, in this unfavourable group of pa-
tients with far advanced disease and refractory
ascites, i.p. bevacizumab was well tolerated. However,
the i.p. administration in addition to paracentesis
did neither result in a better symptom control
of malignant ascites nor in a significant prognostic
improvement in patients with advanced gastrointes-
tinal cancer.
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